Systems and methods to improve organ or tissue function and organ or tissue transplant longevity
AssigneeProterris, Inc.
InventorsJeffrey D. Wager, Joseph Wager, Alex Stenzler, David Pinsky, Augustine Choi
Life of this patent
Estimating the term…
Abstract
The present invention provides for systems and methods for inhaled CO therapy to prevent, attenuate, or delay processes that accelerate the loss of organ or tissue function, thereby increasing the lifespan of transplanted organs or tissues, or slowing the decline of native organs or tissues, or delaying the need for replacement of diseased native organs with organ transplants. Such biological processes that are prevented, attenuated, or delayed include chronic persistent inflammation, fibrosis, scarring, as well as immunologic or autoimmune attack.
Claims17
A system for delivering carbon monoxide therapy, comprising:
- a source of gas comprising carbon monoxide (CO),
- a gas metering device operably connected to the CO source,
- a gas mixing device preparing a constant CO dose with air,
- a mixed CO-air delivery unit delivering a constant CO concentration, and
- a computer system programmed to calculate diffusivity of a patient's lungs for CO (DLCO) with a baseline carboxyhemoglobin (CO-Hb) level and a second CO-Hb level measured after a first delivered CO dose;
- the computer system further programmed to calculate, based on said DLCO, a second CO dose for reaching a target CO-Hb level at a specified duration;
- wherein the computer system is integrated with the gas metering device to control adjustment of said second CO dose.
A system for delivering carbon monoxide therapy, comprising:
- a source of gas comprising carbon monoxide (CO),
- a gas metering device operably connected to the CO source,
- a gas mixing device preparing a constant CO dose with air,
- a mixed CO-air delivery unit delivering a constant CO concentration independent of respiratory rate, functional residual capacity, or tidal volume, and
- a computer system programmed to calculate:
- (1) diffusivity of a patient's lungs for CO (DLCO) with a baseline carboxyhemoglobin (CO-Hb) level and a second CO-Hb level measured after a first delivered CO dose;
- (2) a second dose for reaching a target CO-Hb level at a specified duration based on said DLCO;
- and
- (3) a third CO dose for maintaining the target CO-Hb level based on said DLCO;
- and
- wherein the computer system is integrated with the gas metering device to control adjustment of said second CO dose.
Dependencies are inferred from the claim text.